Sun Pharma Q4 FY26 Results: Net Profit Surges 26% to ₹2,714 Crore — India Business Leads the Charge
By Published on 24 May 2026.
Sun Pharma Q4 FY26 Results
India’s pharmaceutical giant Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA | BSE: 524715) delivered a strong set of numbers for the fourth quarter of financial year 2025–26 (Q4 FY26). The company declared its results on May 22, 2026, reporting a 26% jump in net profit driven by robust domestic formulation growth, expanding market share, and steady momentum in its global innovative medicines portfolio.
For investors, pharma enthusiasts, and stock market watchers, here is a complete breakdown of Sun Pharma’s Q4 FY26 performance.
Q4 FY26 Highlights at a Glance
Sun Pharma posted consolidated net profit of ₹2,714.03 crore for the January–March 2026 quarter, compared to ₹2,149.88 crore in the same quarter of the previous year — marking a growth of 26.24% year-on-year (YoY). Total revenue from operations rose 12.75% YoY to ₹14,611.79 crore, up from ₹12,955 crore in Q4 FY25.
Profit Before Tax (PBT) for the quarter stood at ₹3,551.34 crore, reflecting a growth of 9.12% YoY. EBITDA came in at ₹3,954.2 crore, up 6.4% YoY, though the EBITDA margin moderated slightly to 27.1% from 28.7% a year earlier.
R&D investment for Q4 FY26 stood at ₹975.7 crore, which was 6.7% of quarterly sales, underlining the company’s continued focus on building its innovative pipeline.
Sun Pharma Q4 FY26 vs Q4 FY25 — Key Financial Metrics
| Financial Metric | Q4 FY26 | Q4 FY25 | YoY Growth |
| Net Profit (₹ Crore) | 2,714.03 | 2,149.88 | +26.24% |
| Revenue from Operations (₹ Crore) | 14,611.79 | 12,955.00 | +12.75% |
| Profit Before Tax (₹ Crore) | 3,551.34 | 3,254.35 | +9.12% |
| EBITDA (₹ Crore) | 3,954.20 | 3,716.10 | +6.40% |
| EBITDA Margin | 27.1% | 28.7% | -160 bps |
| R&D Expense (₹ Crore) | 975.70 | 816.60 | +19.49% |
| India Formulation Sales (₹ Crore) | 4,835.90 | 4,213.00 | +14.80% |
India Business: Strongest Pillar of Growth
The domestic market remained Sun Pharma’s most significant growth driver in Q4 FY26. India formulation sales climbed 14.8% YoY to reach ₹4,835.9 crore, accounting for 33.2% of total consolidated sales during the quarter.
Key therapy areas contributing to this domestic growth included cardiology, gastroenterology, central nervous system (CNS), and orthopaedics, where patient demand remained healthy and consistent. For the full year FY26, India formulation sales grew 14% to ₹19,290.4 crore, affirming strong underlying demand across therapeutic segments.
Importantly, Sun Pharma maintained its position as India’s No. 1 pharmaceutical company. According to the Pharmarack MAT March 2026 report, the company’s domestic market share expanded from 8.1% to 8.4% — the highest market share gain since the Ranbaxy acquisition, as acknowledged by Managing Director Kirti Ganorkar. The company also holds the No. 1 ranking by prescriptions in 11 different doctor categories, as per the SMSRC (Nov–Feb 2026) report.
During Q4 FY26 alone, Sun Pharma launched 11 new products, while the full year FY26 saw 37 new product launches across various therapy segments.
Segment-Wise Sales Performance — Q4 FY26
| Geography / Segment | Q4 FY26 Sales | YoY Change | % of Consolidated Sales |
| India Formulations | ₹4,835.9 Crore | +14.8% | 33.2% |
| US Formulations | $459 Million | -1.1% | ~28.8% |
| Emerging Markets | $306 Million | +17.4% | 19.2% |
| Global Innovative Medicines | $354 Million | +20.1% | 22.2% |
| API (External Sales) | ₹673.9 Crore | +26.4% | — |
US Business: Innovative Medicines Offset Generic Weakness
The United States market, which contributed approximately 28.8% of consolidated Q4 sales, delivered $459 million in formulation revenues — a 1.1% decline YoY. The dip was driven by continued pressure in the generics business. However, the growing strength of innovative medicines helped offset this weakness, preventing a sharper fall.
For the full year FY26, US formulation sales stood at $1,904 million, marginally lower than $1,921 million in FY25. US Innovative Medicines revenues have now surpassed $1 billion for the full year — a landmark milestone highlighted by the management.
Sun Pharma currently has 552 approved ANDAs in the US market and 122 ANDA filings awaiting US FDA approval, including 28 tentative approvals. During Q4, the company filed 7 ANDAs and received approval for 2 ANDAs.
Emerging Markets and Global Innovative Medicines
Sun Pharma’s Emerging Markets segment delivered impressive growth, with quarterly revenues rising 17.4% YoY to $306 million. For the full year, Emerging Markets revenues grew 13.6% to $1.27 billion, highlighting successful geographical diversification.
Global Innovative Medicines was another standout performer, with quarterly revenues of $354 million, marking a 20.1% YoY jump and contributing 22.2% of consolidated quarterly sales. For FY26 as a whole, Global Innovative Medicines revenues rose 16.8% to $1,420 million, reinforcing that the company’s strategic pivot toward specialty and innovative drugs is bearing fruit.
FY26 Full Year Performance Summary
For the complete financial year ended March 31, 2026, Sun Pharma delivered healthy performance across the board:
* Full Year Net Profit: ₹11,479 crore — up 5% YoY
* Full Year Revenue from Operations: ₹58,220 crore — up 11.9% YoY
* Full Year EBITDA Margin: 30.3% — supported by operational efficiency
Dividend Announcement
The Board of Directors has recommended a final dividend of ₹5 per equity share (face value ₹1 each) for FY26, subject to shareholder approval at the company’s 34th Annual General Meeting (AGM). Combined with the interim dividend of ₹11 per share already paid during the year, the total dividend for FY26 stands at ₹16 per equity share, in line with the FY25 total dividend payout.
FY26 Full Year Financial Overview vs FY25
| Parameter | FY26 | FY25 | Growth |
| Total Revenue (₹ Crore) | 58,220 | 52,041 | +11.9% |
| Net Profit (₹ Crore) | 11,479 | 10,932 | +5.0% |
| India Formulation Sales (₹ Crore) | 19,290 | 16,921 | +14.0% |
| US Formulation Sales ($ Million) | 1,904 | 1,921 | -0.9% |
| Emerging Markets Sales ($ Million) | 1,270 | 1,117 | +13.6% |
| Innovative Medicines Sales ($ Million) | 1,420 | 1,216 | +16.8% |
| EBITDA Margin | 30.3% | — | — |
| Total Dividend per Share | ₹16 | ₹16 | Unchanged |
Management Commentary & FY27 Outlook
Managing Director Kirti Ganorkar highlighted that the full-year FY26 performance reflected several significant achievements: the highest domestic market share gain since the Ranbaxy acquisition, crossing the $1 billion milestone in US Innovative Medicines, and sustained growth momentum in ex-US innovative medicines.
The company also announced the Organon acquisition, which is expected to further accelerate Sun Pharma’s transformation into a leading global pharmaceutical company.
Founder and Executive Chairman Dilip Shanghvi stated that the company’s innovative R&D pipeline currently includes five novel entities in clinical stages. For FY27, the company has guided for high single-digit consolidated top-line growth, while R&D expenditure is expected to remain in the 6–7% of sales range.
Frequently Asked Questions (FAQ) — People Also Ask
Q1. What is Sun Pharma’s net profit in Q4 FY26?
Sun Pharma reported a consolidated net profit of ₹2,714.03 crore in Q4 FY26, which is a 26.24% increase compared to ₹2,149.88 crore in Q4 FY25.
Q2. What is Sun Pharma’s revenue in Q4 FY26?
The company’s total revenue from operations in Q4 FY26 was ₹14,611.79 crore, reflecting a growth of 12.75% year-on-year.
Q3. What is the dividend declared by Sun Pharma for FY26?
Sun Pharma’s board has recommended a final dividend of ₹5 per share for FY26. Including the interim dividend of ₹11 per share paid earlier, the total FY26 dividend is ₹16 per equity share.
Q4. How did Sun Pharma perform in the India market in Q4 FY26?
India formulation sales grew 14.8% YoY to ₹4,835.9 crore, contributing 33.2% of total consolidated sales. Sun Pharma’s domestic market share also increased from 8.1% to 8.4%.
Q5. What happened to Sun Pharma’s US sales in FY26?
US formulation sales declined marginally by 0.9% for the full year FY26 to $1,904 million, largely due to weakness in generics. However, US Innovative Medicines revenues crossed the $1 billion milestone for the full year.
Q6. What is Sun Pharma’s EBITDA margin for Q4 FY26?
Sun Pharma’s EBITDA margin for Q4 FY26 stood at 27.1%, compared to 28.7% in Q4 FY25. For the full year FY26, EBITDA margin improved to 30.3%.
Q7. What is Sun Pharma’s FY27 revenue growth guidance?
The company has guided for high single-digit consolidated top-line growth in FY27, subject to the regulatory environment and macroeconomic conditions.
Q8. How many new products did Sun Pharma launch in FY26?
Sun Pharma launched a total of 37 new products in FY26, including 11 new product launches during Q4 FY26 alone.
Conclusion
Sun Pharma’s Q4 FY26 results paint a picture of a pharmaceutical powerhouse firing on most cylinders. While the US generics business continues to face pressure, the company’s rapidly expanding India business, surging Emerging Markets revenues, and growing global Innovative Medicines portfolio are collectively building a more resilient and diversified revenue base. The Organon acquisition, combined with a strong pipeline of five novel entities in clinical development, sets Sun Pharma on a promising growth trajectory heading into FY27. With consistent dividend payouts and market leadership in India firmly intact, Sun Pharma remains a compelling stock to watch in the Indian pharma sector.
Disclaimer
This blog does not provide financial, investment, or trading advice. All content is for educational and informational purposes only. Please consult a certified financial advisor before making any investment decisions. The author will not be responsible for any financial losses incurred
